Research progress in colitis-induced hepatic barrier dysfunction

doi:10.16352/j.issn.1001-6325.2022.01.022

Abstract

Abstract: Liver barrier functions as a main structure to protect the liver from exogenous harmful substances and play an important role in maintaining secretion function, regulating bile transport and intercellular information transmission. Liver barrier protein alteration and barrier dysfunction can be induced by endotoxin, inflammatory cytokines and bile acids, which may be involved in the occurrence of colitis-related liver diseases. To explore the outcomes and underlying mechanism of intestinal inflammation on liver barrier function may support the understanding of pathogenesis of colitis-related liver diseases and thus provide clues and basic information for the prevention and treatment of colitis-related liver diseases.

Key words: colitis, liver barrier, endotoxin, bile acids, inflammatory cytokines

CLC Number:

R972

SHU Meng-xuan, YUAN Fang-chen, ZHOU Meng-qi, TU Shi-yan, XU Yue, QIN Hong-yan. Research progress in colitis-induced hepatic barrier dysfunction[J]. Basic & Clinical Medicine, 2022, 42(1): 149-153.

References

[1]Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders [J]. J Crohns Colitis, 2017, 11:649-670.
[2]Zeisel MB, Dhawan P, Baumert TF. Tight junction proteins in gastrointestinal and liver disease [J]. Gut, 2019, 68:547-561.
[3]Gizard E, Ford AC, Bronowicki JP, et al. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease [J]. Aliment Pharmacol Ther, 2014, 40:3-15.
[4]Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and manage-ment of crohn's disease 2016: Part 1: diagnosis and medical management [J]. J Crohns Colitis, 2017, 11:3-25.
[5]Dongaonkar RM, Stewart RH, Quick CM, et al. Hepatic transudation barrier properties [J]. Microcirculation, 2018, 25:1043-1057.
[6]Şimşek T, Ersoy ÖF, Özsoy Z, et al. Effect of sildenafil citrate on the liver structure and function in obstructive jaundice: an experimental study [J]. Turk J Surg, 2018, 34: 111-116.
[7]Mazzon E, Puzzolo D, Caputi AP, et al. Role of IL-10 in hepatocyte tight junction alteration in mouse model of experimental colitis [J]. Mol Med, 2002, 8:353-366.
[8]Mazzon E, Cuzzocrea S. Role of iNOS in hepatocyte tight junction alteration in mouse model of experimental colitis [J]. Cell Mol Biol, 2003, 49:45-57.
[9]Cheng C, Tan J, Qian W, et al. Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: attention to the gut-vascular barrier dysfunction [J]. Life Sci, 2018, 209:157-166.
[10]饶艳霞, 陈洁, 吴亦, 等. DSS诱导溃疡性结肠炎大鼠模型肝脏紧密连接蛋白的表达改变[J]. 临床儿科杂志, 2012, 30:967-972.
[11]Lora L, Mazzon E, Martines D, et al. Hepatocyte tight-junctional permeability is increased in rat experimental colitis [J]. Gastroenterology, 1997, 113:1347-1354.
[12]Balistreri WF. Hepatobiliary complications of inflammatory bowel disease: overview of the issues [J]. Inflamm Bowel Dis, 1998, 4:220-224.
[13]Gabele E, Dostert K, Hofmann C, et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH [J]. J Hepatol, 2011, 55:1391-1399.
[14]Reiling J, Bridle KR, Gijbels M, et al. Low-dose lipopolysaccharide causes biliary injury by blood biliary barrier impairment in a rat hepatic ischemia reperfusion model [J]. Liver Transpl, 2017, 23:194-206.
[15]Correa PR, Guerra MT, Leite MF, et al. Endotoxin unmasks the role of gap junctions in the liver [J]. Biochem Biophys Res Commun, 2004, 322:718-726.
[16]Theodorakis NG, De Maio A. Cx32 mRNA in rat liver: effects of inflammation on poly(A) tail distribution and mRNA degradation [J]. Am J Physiol, 1999, 276:R1249-1257.
[17]De Maio A, Gingalewski C, Theodorakis NG, et al. Interruption of hepatic gap junctional communication in the rat during inflammation induced by bacterial lipopolysac-charide [J]. Shock, 2000, 14:53-59.
[18]Romualdi A, Niessen H, Dombrowski F, et al. Quantita-tive analysis of gap-junctional intercellular communication in precision-cut mouse liver slices [J]. Cell Tissue Res, 2002, 307:315-320.
[19]Ochoa-Sanchez R, Rose CF. Pathogenesis of hepatic encephalopathy in chronic liver disease [J]. J Clin Exp Hepatol, 2018, 8:262-271.
[20]Balasubramaniyan V, Dhar DK, Warner AE, et al. Importance of Connexin-43 based gap junction in cirrhosis and acute-on-chronic liver failure [J]. J Hepatol, 2013, 58:1194-1200.
[21]Zeng H, Umar S, Rust B, et al. Secondary bile acids and short chain fatty acids in the colon: a focus on colonic microbiome, cell proliferation, inflammation, and cancer [J]. Int J Mol Sci, 2019, 20:1214-1233.
[22]de Vries E, Beuers U. Management of cholestatic disease in 2017 [J]. Liver Int, 2017, 37:123-129.
[23]Takakuwa Y, Kokai Y, Sasaki K, et al. Bile canalicular barrier function and expression of tight-junctional mole-cules in rat hepatocytes during common bile duct ligation [J]. Cell Tissue Res, 2002, 307:181-189.
[24]Yang T, Mei H, Xu D, et al. Early indications of ANIT-induced cholestatic liver injury: alteration of hepatocyte polarization and bile acid homeostasis [J]. Food Chem Toxicol, 2017, 110:1-12.
[25]Khan HA, Ahmad MZ, Khan JA, et al. Crosstalk of liver immune cells and cell death mechanisms in different murine models of liver injury and its clinical relevance [J]. Hepatobiliary Pancreat Dis Int, 2017, 16:245-256.